ASX · HMD.AX
HeraMED Limited
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
Loading market information…
ASX · MAP.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:33 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Microba Life Sciences Limited’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Microba Life Sciences Limited’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Microba Life Sciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Dec 30, 2023 |
| -A$0.03 |
| A$3.27M-25.62% vs estimate |
| Q4 2023 | Jun 30, 2023 | -A$0.02 | A$3.27M-0.95% vs estimate |
|---|
| Q2 2023 | Dec 30, 2022 | -A$0.02 | A$2.15M+2.45% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
A$0.15A$0.00 (0.0%)
Nova Eye Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
A$0.15A$0.00 (0.0%)
Next Science Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
A$0.04+A$0.00 (0.0%)
Emyria Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.08+A$0.00 (+5.0%)
BCAL Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 45.81% below the high.
A$0.06+A$0.00 (0.0%)
Rhythm Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 77.5% below the high.
A$0.14A$0.00 (0.0%)
INOVIQ Ltd’s quoted price sits in the lower half of its reported 52-week range, 76.11% below the high.
A$0.04-A$0.00 (-2.22%)
IDT Australia Limited’s quoted price sits in the lower half of its reported 52-week range, 29.03% below the high.
